Showing posts with label peritoneal. Show all posts
Showing posts with label peritoneal. Show all posts
Wednesday, April 04, 2012
Phase 2 Study Update of Selumetinib for Ovarian Cancer - MPR
Blogger's Note: more info req'd eg. side effects....
Phase 2 Study Update of Selumetinib for Ovarian Cancer - MPR
Array BioPharma announced results of a Phase 2 trial of selumetinib in women with recurrent low-grade serous ovarian or peritoneal cancer.
In the trial, 52 women each received 100mg doses of selumetinib orally twice daily in four-week cycles until disease progression or toxicity. The median number of cycles received was 4.5; 33% underwent ≥12 cycles. Prior to the trial, 58% of the patients in the trial had received three or more rounds of chemotherapy.
A disease control rate, defined as either complete or partial response or progression-free survival or progression-free survival of greater than 6 months, occurred in 81% of patients. Eight patients had complete (1) or partial (7) responses, and 34 (63%) had progression-free survival of >6 months. The median survival rate without cancer progression was 11 months.
Selumetinib is an anti-cancer drug in Phase 2 development in a range of tumors. It is a small molecule MEK inhibitor that targets a key position in the Ras-Raf-MEK-ERK signaling pathway. MEK has been shown to be frequently activated in cancer, in particular in tumors that have mutations in the RAS and RAF pathways.
For more information call (877) MED-CHEM or visit www.arraybiopharma.com
add your opinions
low grade serous ovarian
,
peritoneal
,
phase 11 clinical trial
,
selumetinib
Tuesday, July 06, 2010
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas
Objective.
To assess the morbidity and mortality associated with extensive upper abdominal surgery (EUAS) performed during primary cytoreduction for advanced ovarian carcinoma.
Subscribe to:
Posts
(
Atom
)